CSL (BMV:CSL N) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

CSL N Overzicht aandelen

Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

Over het bedrijf

CSL N fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	3/6
Prestaties in het verleden	2/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 17.87% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Heeft een hoog schuldenniveau

CSL Limited Concurrenten

Gilead Sciences

NasdaqGS:GILD

US$105.3b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$109.3b

Amgen

NasdaqGS:AMGN

US$171.8b

Celltrion

KOSE:A068270

₩39.8t

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor CSL
Historische aandelenkoersen
Huidige aandelenkoers	AU$3,635.42
52 Week Hoogtepunt	AU$3,635.42
52 Week Laag	AU$3,635.42
Bèta	0.20
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-15.46%
5 jaar verandering	n/a
Verandering sinds IPO	27.33%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	CSL N	MX Biotechs	MX Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe CSL N presteerde ten opzichte van de MX Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe CSL N presteerde ten opzichte van de MX markt.

Prijsvolatiliteit

Is CSL N's price volatile compared to industry and market?
CSL N volatility
CSL N Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiele aandelenkoers: CSL N heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van CSL N in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1916	30,000	Paul McKenzie	www.csl.com.au

CSL Limited Samenvatting

Hoe verhouden de winst en inkomsten van CSL zich tot de beurswaarde?
CSL N fundamentele statistieken
Marktkapitalisatie	Mex$1.73t
Inkomsten(TTM)	Mex$38.12b
Inkomsten(TTM)	Mex$210.68b

45.3x

Koers/Winstverhouding

8.2x

P/S-verhouding

Is CSL N overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CSL N resultatenrekening (TTM)
Inkomsten	US$11.70b
Kosten van inkomsten	US$5.56b
Brutowinst	US$6.15b
Overige uitgaven	US$4.03b
Inkomsten	US$2.12b

Laatst gerapporteerde inkomsten

Dec 31, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	4.39
Brutomarge	52.52%
Nettowinstmarge	18.09%
Schuld/Eigen Vermogen Verhouding	59.7%

Hoe presteerde CSL N op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

1.1%

Huidig dividendrendement

51%

Uitbetalingsratio

CSL N Overzicht aandelen

Beloningen

Risicoanalyse

CSL Limited Concurrenten

NasdaqGS:GILD

US$105.3b

NasdaqGS:REGN

US$109.3b

NasdaqGS:AMGN

US$171.8b

KOSE:A068270

₩39.8t

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

Recent updates

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Independent Non Executive Director recently bought Mex$939k worth of stock

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Non-Independent Non-Executive Director recently sold Mex$87m worth of stock

Upcoming dividend of US$1.18 per share

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

CSL Limited Samenvatting

45.3x

8.2x

Inkomsten en omzet

Dividenden

1.1%

51%